Similar articles

• Abacavir and increased risk of myocardial infarction.

  Post FA, Campbell LJ. Post FA, et al. Lancet. 2008 Sep 6;372(9641):803; author reply 804-5. doi: 10.1016/S0140-6736(08)61330-6. Lancet. 2008. PMID: 18774412 No abstract available.
• Abacavir and cardiovascular risk: reviewing the evidence.

  Costagliola D, Lang S, Mary-Krause M, Boccara F. Costagliola D, et al. Curr HIV/AIDS Rep. 2010 Aug;7(3):127-33. doi: 10.1007/s11904-010-0047-3. Curr HIV/AIDS Rep. 2010. PMID: 20521126 Review.
• Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies.

  Dorjee K, Choden T, Baxi SM, Steinmaus C, Reingold AL. Dorjee K, et al. Int J Antimicrob Agents. 2018 Nov;52(5):541-553. doi: 10.1016/j.ijantimicag.2018.07.010. Epub 2018 Jul 21. Int J Antimicrob Agents. 2018. PMID: 30040992 Free PMC article.
• Abacavir and cardiovascular risk in HIV-infected patients: does T lymphocyte hyperactivation exert a pathogenic role?

  Marchetti G, Casana M, Tincati C, Bellistrì GM, Monforte Ad. Marchetti G, et al. Clin Infect Dis. 2008 Dec 1;47(11):1495-6. doi: 10.1086/593110. Clin Infect Dis. 2008. PMID: 18986270 No abstract available.
• Comparing implications of cardiovascular risk of abacavir and integrase inhibitors: why scientific community is confused and timid?

  Guaraldi G, Milic J. Guaraldi G, et al. AIDS. 2023 May 1;37(6):1005-1008. doi: 10.1097/QAD.0000000000003518. AIDS. 2023. PMID: 37017023 No abstract available.